It's time for a fresh leadership team to try turning around the troubled generic drug giant Teva Pharmaceutical Industries Ltd. now that the new CEO Kare Schultz has made his first big move, but the task won't be easy.
Teva announced a new organizational structure and corporate leadership team Nov. 27 that will almost entirely change the big pharma's top ranks. Head of R&D Michael Hayden, Global Specialty Medicines CEO Rob Koremans and Global Generic Medicines CEO Dipankar Bhattacharjee all will leave the company at the end of the year